Open access
Research Article
9 November 2016

Interspecies Interactions between Clostridium difficile and Candida albicans

ABSTRACT

The facultative anaerobic polymorphic fungus Candida albicans and the strictly anaerobic Gram-positive bacterium Clostridium difficile are two opportunistic pathogens residing in the human gut. While a few studies have focused on the prevalence of C. albicans in C. difficile-infected patients, the nature of the interactions between these two microbes has not been studied thus far. In the current study, both chemical and physical interactions between C. albicans and C. difficile were investigated. In the presence of C. albicans, C. difficile was able to grow under aerobic, normally toxic, conditions. This phenomenon was neither linked to adherence of bacteria to hyphae nor to biofilm formation by C. albicans. Conditioned medium of C. difficile inhibited hyphal growth of C. albicans, which is an important virulence factor of the fungus. In addition, it induced hypha-to-yeast conversion. p-Cresol, a fermentation product of tyrosine produced by C. difficile, also induced morphological effects and was identified as an active component of the conditioned medium. This study shows that in the presence of C. albicans, C. difficile can persist and grow under aerobic conditions. Furthermore, p-cresol, produced by C. difficile, is involved in inhibiting hypha formation of C. albicans, directly affecting the biofilm formation and virulence of C. albicans. This study is the first detailed characterization of the interactions between these two gut pathogens.
IMPORTANCE Candida albicans and Clostridium difficile are two opportunistic pathogens that reside in the human gut. A few studies have focused on the prevalence of C. albicans in C. difficile-infected patients, but none have shown the interaction(s) that these two organisms may or may not have with each other. In this study, we used a wide range of different techniques to better understand this interaction at a macroscopic and microscopic level. We found that in the presence of C. albicans, C. difficile can survive under ambient aerobic conditions, which would otherwise be toxic. We also found that C. difficile affects the hypha formation of C. albicans, most likely through the excretion of p-cresol. This ultimately leads to an inability of C. albicans to form a biofilm. Our study provides new insights into interactions between C. albicans and C. difficile and bears relevance to both fungal and bacterial disease.

INTRODUCTION

Clostridium difficile is a Gram-positive, obligate anaerobic, endospore-forming bacterium that is one of the most important causes of health care-associated infections (1, 2). Patients infected with C. difficile show symptoms that range from mild diarrhea to severe colitis—inflammation of the large intestine—that can lead to death (3). C. difficile infections (CDI) generally occur after use of broad-spectrum antibiotics that disrupt the normal gut microbiota. This dysbiosis permits C. difficile to colonize the large intestine, where the organism produces the toxins that are primarily responsible for the symptoms associated with CDI (4).
Since the early 2000s, there have been rising rates of CDI in Canada (5, 6), the United States (7), and Europe (8, 9). The current estimate is that 500,000 cases of CDI are diagnosed each year in the United States and 124,000 in Europe (1). Of these 500,000 cases, an estimated 4% of the patients never recover and eventually die (2, 10). The costs associated with CDI, an estimated $1 to $3 billion annually in the United States alone, represent a significant problem in health care settings (11, 12).
About 1 to 3% of hospitalized patients become infected with C. difficile, of which 25% will experience recurrent infections (13). These high relapse rates are partly due to the disruption of the healthy gut microbiota and the associated metabolome by antibiotics (14). Moreover, C. difficile is naturally resistant to several broad-spectrum antibiotics used in current medicine. The combined effect is that C. difficile can thrive while other bacteria in the intestinal flora suffer (15, 16). The risk of CDI declines once antibiotic treatment is completed and the gut microbiome can restore its original diversity and strength (2).
Like C. difficile, Candida albicans can be part of the gut microbiome of healthy individuals (17). C. albicans is a facultative anaerobic fungus that can grow in yeast, pseudohyphal, and hyphal morphologies and can persist in the gastrointestinal (GI) tract for prolonged periods of time (18). However, when the host’s immune system is compromised, C. albicans can cause a range of infections (19, 20). The virulence of C. albicans depends on its morphology; the filamentous morphology (called hypha) is invasive and poses a threat to the host, whereas the yeast and pseudohyphal morphologies do not (2123).
The morphology of C. albicans is relevant to its interactions with other microorganisms. For instance, Staphylococcus aureus can invade the host by adhering to the hyphae of C. albicans (24). In addition, C. albicans can form heterogeneous biofilms with other microorganisms. These biofilms allow microorganisms to thrive under conditions that would normally be inhospitable (e.g., conferring vancomycin resistance to S. aureus [2527]). Another bacterial species taking advantage of the microenvironment in the C. albicans biofilm is Clostridium perfringens, which can grow under normally toxic aerobic conditions when cocultured with C. albicans (26).
In addition to specific interactions between Candida and the host and Candida and the microbiome, C. albicans may be a key player of the gut mycobiota. The general role of mycobiota in the gastrointestinal tract is largely unexplored (28). Recent studies have illustrated a clear role for C. albicans in the postantibiotic recolonization of the cecum (29). This potentially decreases the chance of C. difficile relapse, as it shortens the duration of dysbiosis—the window of opportunity for C. difficile. Several recent studies have tried to define a possible correlation between C. albicans overgrowth and the presence of C. difficile. However, both positive (3032) and negative correlations (33, 34) have been reported, and it remains uncertain how these two organisms interact.
In the current study, we investigated both the physical and chemical interactions between C. albicans and C. difficile. We show that C. albicans allows C. difficile to survive ambient oxygen levels in the absence of C. albicans biofilms and that hypha formation and subsequent biofilm formation by C. albicans are inhibited by C. difficile, most likely through the production of p-cresol.

RESULTS

Coculture with C. albicans allows C. difficile to grow and survive under aerobic conditions.

While C. albicans is commonly cultured under aerobic conditions (35), it is able to grow anaerobically (36). C. difficile, however, is a strict anaerobic organism, and even small amounts of molecular oxygen are toxic (37). As the gut represents an anaerobic niche (38), the ability of C. albicans, C. difficile, and the combination of both organisms to grow under anaerobic conditions was determined. As expected, the optical density at 600 nm (OD600) of the C. difficile monoculture reached the stationary phase (OD600 of 1.97) after 30 h of growth (Fig. 1A), whereas the C. albicans monoculture showed limited growth (final OD600 of 0.43).
FIG 1
FIG 1 (A) OD600 values of monoculture of C. difficile (circles), monoculture of C. albicans (squares), and coculture of both organisms (triangles) under anaerobic conditions. All three conditions showed increasing OD600 values over time. The coculture of C. difficile with C. albicans and the monoculture of C. difficile reached similar OD600 values after 30 h. (B) Enumeration of C. difficile from monoculture and from coculture with C. albicans under anaerobic and aerobic conditions after 0 (black) and 24 (gray) h. Both monocultured and cocultured C. difficile grown under anaerobic conditions showed an increase in viable numbers. Under aerobic conditions, growth of monocultured C. difficile resulted in decreased viability, while C. difficile cocultured with C. albicans showed increased viability. Experiments were performed three times, and representative examples are shown.
The coculture of C. difficile and C. albicans reached an OD600 value after 30 h that was comparable to that of the C. difficile monoculture. As the OD data do not prove whether C. difficile is responsible for this growth in coculture, additional plate counts were performed to determine bacterial growth. Anaerobic conditions supported the growth of C. difficile in monoculture, resulting in a 2-Log increase in viable counts (Fig. 1B). Under aerobic conditions, there was a 4-Log decrease in viability, consistent with the strict anaerobic nature of C. difficile. In contrast, coculturing C. difficile with C. albicans under aerobic conditions resulted in a 1-Log increase in the growth of C. difficile. These findings suggest that C. difficile is viable and able to replicate under aerobic conditions when cocultured with C. albicans.

C. difficile does not adhere to hyphae of C. albicans.

The hyphae of C. albicans are attractive surfaces for bacteria to adhere to. Biofilm formation by the anaerobic bacterium C. perfringens on hyphae of C. albicans has been demonstrated previously (26). Because adherence is an important hallmark for heterogeneous biofilm formation, the adherence of C. difficile to C. albicans hyphae was evaluated using the Bioflux microfluidics platform.
The interaction of C. difficile with hyphae was limited under the conditions tested (see Fig. S1 in the supplemental material). Adhesion was mostly absent, but when bacteria adhered, they mostly did so at the tips of growing hyphae.
We conclude that, although C. albicans allows C. difficile to grow under normally toxic levels of oxygen, this is probably not mediated by aggregation or biofilm formation, in contrast to what has been suggested for other anaerobic bacteria.

Coculture with C. difficile affects the morphology of C. albicans.

In the experiments described above, we established that C. difficile neither significantly adheres to hyphae nor stimulates biofilm formation of C. albicans. To investigate the presence of a chemical interaction between the two organisms, anaerobic growth in mono- and coculture was evaluated using microscopy.
C. albicans is a polymorphic fungus, and the morphological switch is an important virulence factor (23). In anaerobic monoculture, C. albicans displayed predominantly hyphal growth, with the lengths of hyphae exceeding 100 µm after 4 h of growth (Fig. 2A). In coculture, this was different, with C. albicans growing mainly in yeast or pseudohyphal morphology (Fig. 2B).
FIG 2
FIG 2 Morphology of C. albicans in anaerobic monoculture (A) and cocultured with C. difficile (B). In the monoculture, hyphae were clearly visible. Note that this is not one single hypha but multiple intertwined hyphae. In coculture with C. difficile, C. albicans was mostly observed in the yeast and pseudohyphal morphologies. All images have the same brightness and contrast adjustments. Scale bars indicate 100 µm; note that the scale for panel B is different to show the presence of C. difficile cells.

The morphological shift does not require the physical presence of C. difficile.

Several bacterial species are known to secrete products that inhibit the yeast-to-hypha transition (39, 40). We therefore hypothesized that C. difficile produces a chemical signal that prevents and/or reverses hyphal growth of C. albicans. Such a chemical signal should persist in the absence of C. difficile cells. To investigate this, aerobically grown C. albicans was exposed to conditioned medium of C. difficile. We found that under such conditions, C. albicans grew almost exclusively in the yeast morphology (Fig. 3A and B), with few cells exhibiting a pseudohyphal morphology.
FIG 3
FIG 3 C. albicans grown in conditioned medium of C. difficile (A and B) and C. perfringens (E and F) at t = 0 min and t = 180 min. No hyphae are observed for C. albicans grown in C. difficile-conditioned medium, in contrast to substantial hypha formation by C. albicans growing in conditioned medium from C. perfringens. Note that lack of hyphae in C. difficile-conditioned medium caused some yeasts to wash out of the microchannel. All images have the same brightness and contrast adjustments. The scale bar indicates 50 µm.
This effect cannot be attributed to nutrient depletion by dilution with the C. difficile-conditioned medium, as C. albicans exclusively showed hyphal growth when brain heart infusion (BHI) was diluted 1:1 with phosphate-buffered saline (PBS) (Fig. 3C and D). Moreover, the inhibition of hyphal growth seemed specific to C. difficile, as conditioned medium obtained from C. perfringens failed to inhibit the morphological switch (Fig. 3E and F).

A stationary-phase signal produced by C. difficile can reverse hyphal growth of C. albicans.

Many bacterial products that affect morphological switching of C. albicans are produced during specific phases of growth (41, 42). We hypothesized that the C. difficile-dependent effects we describe above were also growth phase dependent. To test this hypothesis, the effects of conditioned medium derived from C. difficile cultures after 8, 24, and 48 h of incubation on C. albicans morphology were determined using real-time microscopy. This allowed a quantitative analysis of the fungal morphology over time.
In the time allowed for adherence to the microchannel, C. albicans initiated hypha formation; for this reason, the proportion of hyphae at 0 min is about 60% for all conditions. The control for nutrient depletion (BHI diluted 1:1 with PBS) showed increasing proportions of hyphae, up to 90%, compared to the proportions of yeasts and pseudohyphae during the time of the experiment (Fig. 4A). Upon the addition of conditioned medium from an 8-h-old culture of C. difficile, an increase from 60% to 80% hyphae in the first 2 h of exposure was noted, followed by a decline in the proportion of hyphae back to starting levels in the following hour. This demonstrates a reversal of hypha formation. The hypha-inhibiting effect was more pronounced when 24-h and 48-h C. difficile-conditioned medium was used, with less than 10% and 5% hyphal morphology, respectively, at the endpoint. Reversal of hypha formation also occurred at increasingly earlier time points in correlation with the age of the conditioned medium: at 130 min for the 8-h-old conditioned medium, 55 min for the 24-h-old conditioned medium, and 30 min for the 48-h-old conditioned medium (Fig. 4B to D).
FIG 4
FIG 4 Proportions of C. albicans hyphae (black) and yeasts/pseudohyphae (gray) in different media. The images to the right of the graphs show the culture at 180 min. When grown in BHI, hyphae dominated the culture. The culture grown in 8-h-old C. difficile-conditioned medium yielded the same results until a morphological shift occurred at 130 min, after which the proportion of hyphae decreased in favor of the yeast and pseudohyphal morphologies. The shift occurred at earlier time points when 24-h and 48-h conditioned media were used, 55 min and 30 min, respectively. Moreover, the hypha-inhibiting effect is parallel to the age of the conditioned medium. The proportions of yeast and hyphal cells are significantly different between 24-h and 48-h conditioned medium and the control at the 130-min time point and thereafter (P < 0.05). Error bars indicate standard deviations. The scale bar indicates 50 µm.
We conclude that the chemical signal produced by C. difficile is most apparent in stationary growth phase.

p-Cresol is involved in the inhibitory effect on hyphae formation of C. albicans.

We observed that the inhibitory effect on hyphae formation occurred for conditioned medium derived from C. difficile cultures and not for conditioned medium from C. perfringens cultures (Fig. 3). An important characteristic of C. difficile that sets it apart from other clostridia is its ability to produce p-cresol (4-methylphenol), and in contrast to other bacteria, C. difficile can grow in the presence of up to 0.1 to 0.2% (9.25 mM to 18.5 mM) of this compound (4345). We fractionated the conditioned medium of both C. difficile and C. perfringens cultures using high-performance liquid chromatography (HPLC) and analyzed the activity of each fraction on C. albicans morphology.
To determine which fraction should contain the p-cresol, we used fresh BHI spiked with 5% p-cresol. We observed a sharp peak at 13.1 min in the elution profile (Fig. 5A). Analysis of the conditioned medium of C. difficile and C. perfringens after 24 h of growth showed minor peaks at this time point that could not clearly be attributed to p-cresol (Fig. 5A). However, when we compared the 13.1-min fraction (fraction 3) to all other fractions of the C. difficile-conditioned medium in our hypha formation assay, we observed that the fraction that was expected to contain p-cresol showed inhibition of hypha formation similar to that observed in previous assays with conditioned medium (Fig. 5B). It should be noted that the effect is an underestimate, due to dilution of the fraction with the HPLC eluate during elution from the HPLC.
FIG 5
FIG 5 Fractions as they were collected (A) and effect on hyphae of C. albicans of the fraction expected to contain p-cresol compared to the effect of the other fractions (B). (A) The BHI spiked with 5% p-cresol (black) showed a clear peak at 13.1 min (fraction 3). Curves for conditioned media of C. difficile and C. perfringens are in blue and red, respectively. (B) The fraction that was expected to contain p-cresol (fraction 3) resulted in pseudohyphae. A clear time-dependent effect was observed when comparing the effect of fraction 3 to that of the other fractions. The magnification and time points of the sequences are identical.
To provide further evidence that p-cresol is capable of inhibiting hypha formation, we analyzed the effects of different concentrations of p-cresol on hypha formation over time. Because p-cresol is known to be toxic to bacteria in concentrations as low as 0.2% (46), we first determined whether p-cresol has a MIC for C. albicans. The observed MIC was 0.09% p-cresol (wt/vol), comparable to what has been observed for bacteria (47). The addition of p-cresol concentrations from 0.045% up to 0.09% in BHI resulted in inhibition of hypha formation in a concentration-dependent fashion (Fig. 6). Notably, C. albicans cultured in the higher concentrations of p-cresol showed strong swelling of the hyphal tips, consistent with a toxic effect.
FIG 6
FIG 6 Effect of p-cresol on hypha formation of C. albicans. A concentration-dependent effect was observed, with the higher concentrations of p-cresol impairing hyphal elongation. Apparent swelling of the hyphal tip and yeast bud formation was observed. The scale bar indicates 25 µm.
The formation of p-cresol from 4-hydroxyphenylacetic acid (p-HPA) requires the glycyl radical enzyme HpdB, a p-HPA decarboxylase, in C. difficile (48). The gene encoding this enzyme (hpdB/CD0153) is located in an operon that also encodes the proteins of unknown function HpdC (CD0154) and HpdA (CD0155), which are required for reconstitution of HpdB activity in vitro (48, 49). Insertional mutagenesis of either of these genes abolishes p-cresol production (50). To provide genetic evidence that p-cresol contributes to the observed effect on hypha formation, we generated an unmarked mutant of C. difficile in which the entire hpd operon was deleted by allelic exchange (51). PCR analysis showed the expected 3.9-kb deletion (Fig. 7A), and nuclear magnetic resonance (NMR) analysis confirmed that the mutant strain was unable to convert p-HPA to p-cresol (Fig. 7B). In contrast to conditioned medium from a wild-type C. difficile strain, conditioned medium from the C. difficile Δhpd strain did not result in the inhibition of C. albicans hyphal elongation (Fig. 7C). Under all conditions, slight pseudohyphal growth was observed, possibly caused by the richness of the medium. Together, our data suggest that p-cresol, resulting from p-HPA decarboxylase activity, is important for the inhibitory effect of C. difficile on C. albicans hypha formation and elongation.
FIG 7
FIG 7 Effect of the Δhpd mutant on hypha formation of C. albicans. (A) PCR analysis showing the expected 3.9-kb deletion of the hpd gene cluster. (B) The Δhpd strain is unable to convert p-HPA to p-cresol. (C) Effects of 24-h-old conditioned medium of Δhpd and wild-type C. difficile on hyphae of C. albicans. Hypha formation observed in conditioned medium of the Δhpd mutant was similar to that in the control. In contrast, inhibition of hyphal growth was observed in the conditioned medium of wild-type C. difficile.

Wild-type C. difficile, but not the Δhpd mutant, inhibitsC. albicans biofilm formation.

As hypha formation is crucial for the formation of C. albicans biofilms (52) and conditioned medium from C. difficile inhibits this process, we determined the effect of C. difficile on C. albicans biofilm formation. Biofilms of C. albicans were grown in fresh medium or 24-h-old conditioned medium of either wild-type or ΔhpdC. difficile. As a control, fresh medium supplemented with 0.1% p-cresol was included, which is expected to block biofilm formation by inhibition of C. albicans growth. Indeed, we observed a strong reduction in the biofilm assay (~fourfold, P < 0.01). We found that the conditioned medium from the wild-type C. difficile significantly reduced biofilm formation (~1.5-fold, P < 0.05) compared to that in fresh medium (Fig. 8). In contrast, conditioned medium from the C. difficile Δhpd mutant stimulated biofilm formation ~1.5-fold compared to the biofilm formation in fresh medium. Since C. albicans biofilm formation is more pronounced in minimal medium than in rich medium, this could be related to nutrient depletion. Therefore, the actual difference in the biofilm-inhibitory effect between the ΔhpdC. difficile and the wild type is probably larger than comparison with the biofilm formation in fresh medium suggests.
FIG 8
FIG 8 Effect of p-cresol on C. albicans biofilm formation. C. albicans biofilm formation is decreased in the presence of C. difficile 630Δerm-conditioned medium (CM) (P < 0.05). C. albicans biofilm grown in the presence of 0.1% p-cresol is decreased more (P < 0.01). The C. difficile Δhpd-conditioned medium showed increased biofilm formation. Data represent the results from 6 replicates, and error bars indicate standard deviations. We conclude that naturally produced and synthetic p-cresol can inhibit biofilm formation of C. albicans.

DISCUSSION

In this study, we investigated physical and chemical interactions between C. difficile and C. albicans. Two major discoveries are described: (i) C. difficile can survive ambient oxygen levels when cocultured with C. albicans, and (ii) C. difficile produces a secreted compound with inhibitory activity against two virulence factors of C. albicans—yeast-to-hypha transition and biofilm formation.
Multispecies biofilms are able to generate an anaerobic microenvironment that can sustain the growth of obligate anaerobic bacteria (26, 53, 54). This is exemplified by C. albicans and the anaerobic bacterium C. perfringens in a two-species system (26). To date, interactions of this nature between bacteria and Candida all rely on a physical interaction between the two species. Our study shows that this is not the case for C. difficile. Although C. albicans can sustain aerobic growth of C. difficile, we did not observe significant adherence of bacteria to hyphae of C. albicans. Moreover, C. difficile inhibited and reversed hypha formation, a key virulence factor and an essential process for C. albicans biofilm formation. What then underlies the positive effect of C. albicans on the aerobic survival and growth of C. difficile? We consider two, not mutually exclusive explanations. First, the facultative anaerobe C. albicans may reduce the oxygen tension through its metabolism (55), reducing it to levels that can sustain growth of C. difficile. It is important to note that culture methods strongly influence oxygen tension and the heterogeneity therein (56). Second, C. albicans may produce antioxidants. Indeed, C. albicans is known to produce tyrosol, which can act as an antioxidant, and it has recently been shown that the addition of strong antioxidants to culture medium allows the growth of anaerobic bacteria at ambient oxygen levels (57). In either case, there is an important implication of our finding. Vegetative C. difficile cells may be able to survive an oxygenated environment in the context of other species. In nature, most bacteria reside as polymicrobial communities in environments that are not necessarily anaerobic, such as the human oral and skin microbiome, and this greatly expands the ecological niches of C. difficile and, possibly, other obligate anaerobic bacteria.
The interactions between C. difficile and C. albicans bear relevance for both bacterial and fungal disease. Several studies have evaluated the relation between CDI and Candida colonization and/or disease, and both positive and negative associations have been reported. Patients treated for CDI were found to be able to acquire Candida, while Candida levels in precolonized patients showed a reduction of C. albicans during treatment (34). CDI patients were less likely to have C. albicans overgrowth (33), but C. albicans bloodstream infections were reported after a CDI episode (31). Finally, CDI-positive patients were reported to have higher C. albicans colonization rates (30). The interpretation of these findings is difficult, as the reports are largely observational and diverse in patient status (e.g., antibiotic treatment). As both C. albicans and C. difficile are opportunistic pathogens, differences in treatment could result in an environment that favors one pathogen over the other.
In this study, we found that C. albicans allowed C. difficile to grow at ambient oxygen levels. It is believed that there is an oxygen gradient from the proximal (stomach) to distal (rectum) gastrointestinal tract (38) that can affect bacterial virulence and host responses (58) and plays a role in intestinal dysbiosis (59). It is therefore conceivable that C. difficile in hosts colonized by Candida can, under suitable conditions (such as high levels of primary bile acids) (60), colonize a greater niche than the colon alone.
The presence of C. difficile was linked to an absence of C. albicans hyphae. This suggests that invasive Candida infections, originating in the GI tract and potentially leading to candidemia, are less likely to occur in CDI patients. As C. difficile did not inhibit proliferation of the yeast form of C. albicans, superficial candidiasis could still be possible. Inhibition of Candida hypha formation by C. difficile may also be relevant for recurrent CDI. A positive effect of C. albicans on the regeneration of the intestinal flora after antibiotic-induced dysbiosis was recently shown (29), and reestablishment of a diverse gut microbiome is accompanied by a decreasing probability for the development of CDI (2, 10). By inhibiting hypha formation, C. difficile can prolong the window of opportunity for the development of CDI as it competes directly with C. albicans itself or by competing with bacteria in a heterogeneous C. albicans-containing biofilm.
The results from this study suggest an involvement of p-cresol, produced by C. difficile, in the inhibitory effect on C. albicans hypha formation. Cell-free conditioned medium from wild-type C. difficile, but not from an isogenic Δhpd strain, inhibited hypha formation (Fig. 2 to 5, 7, and 8) and reduced biofilm formation of C. albicans (Fig. 8). Fractionation of the conditioned medium showed that the p-cresol-containing fraction inhibited hypha formation, whereas the other fractions did not. Conditioned medium from C. perfringens, which does not produce p-cresol (45, 61), failed to inhibit hyphal formation and biofilm formation. Pure p-cresol was capable of stopping hyphal growth and induced swelling of the hyphal tips (Fig. 6). However, we were unable, to detect p-cresol in conditioned BHI medium (Fig. 5A), consistent with previous findings (50). To validate our C. difficile Δhpd strain (Fig. 7B), medium supplemented with the biosynthetic precursor p-HPA was used, as previously described (50). Both the fractionation of the conditioned medium and the NMR analysis of the p-cresol content of the medium required extensive processing of the sample. As p-cresol is a volatile compound, this could explain our failure to detect it in these experiments. Consistent with this, we note that the complete conversion of p-HPA by the wild-type C. difficile is accompanied by very minor peaks corresponding to p-cresol (Fig. 7B). Though all our experiments support the involvement of p-cresol in the inhibition of hypha formation, we cannot exclude the possibility that C. difficile produces other compounds of metabolic products that also affect C. albicans morphology.
Previously, p-cresol was identified as an antibacterial, and it has been exploited to facilitate the isolation of C. difficile (45, 46). The MIC of p-cresol for C. albicans observed in this study (0.09% wt/vol) is comparable to those for bacteria. To our knowledge, this is the first time that an antifungal effect of p-cresol has been reported. We cannot exclude the possibility that part of the effect of p-cresol on the morphology of C. albicans is related to toxicity. Other signaling compounds (e.g., farnesol [reviewed in reference 62]) and antifungals (e.g., fluconazole [63]) are also toxic at higher levels. Hyphal inhibitors are already being used to treat candidiasis (64, 65), and our finding may lead to enhanced treatment options for C. albicans infections. The mode of action of p-cresol toward C. albicans is unknown. However, the effects on Candida of two compounds that share structural similarities to p-cresol, thymol and carvacrol, have been reported (66). Both compounds cause oxidative stress, damage the antioxidant defense system, and lead to membrane deterioration. It is tempting to speculate that a similar mechanism contributes to the action of p-cresol. Notably, several other phenolic compounds have been reported to positively or negatively affect Candida viability, morphology, and biofilm formation; these include but are not limited to tyrosol (67, 68), p-coumaric acid (69), ferulic acid (70), caffeic acid (71), boric acid (72), and eugenol (73). These observations, together with the identification of more-complex inhibitors (74, 75), may lead to the identification of general structural principles of compounds that govern Candida proliferation and the yeast-to-hypha transition.

MATERIALS AND METHODS

Strains and growth conditions.

The strains used in this study were C. difficile 630Δerm (76, 77) and an isogenic hpd mutant (this study), C. perfringens ATCC 13124 (78), and C. albicans SC5314 (79). Frozen stocks were prepared by adding sterile glycerol (final concentration, 10% [vol/vol]) to a fresh culture and storing at −80°C.
All medium components were purchased at BD unless stated otherwise. Both clostridiae were routinely subcultured on brain heart infusion (BHI) containing 1.5% [wt/vol] Bacto agar at 37°C under anaerobic conditions (10% H2, 10% CO2 in N2). C. albicans was cultured on yeast-peptone-dextrose (YPD) agar (1% [wt/vol] Bacto yeast extract, 2% [wt/vol] Bacto peptone, 2% [wt/vol] dextrose [Merck], 1.5% [wt/vol] Bacto agar) at 30°C under aerobic conditions.
Prior to each experiment, fresh planktonic cultures were prepared by inoculating a single colony of each strain to either BHI or YPD (for both media, the agar was omitted). The clostridia were anaerobically incubated at 37°C for 72 h under agitation. C. albicans was incubated aerobically at 30°C for 16 h under agitation.

Construction of the C. difficile Δhpd strain.

The up- and downstream regions of the hpd operon that are required for p-cresol synthesis (48, 50) were cloned into the pMTL-SC7215 vector (51) using Gibson assembly (80). Primer design was carried out using the NEBuilder tool version 1.10.7 (New England Biolabs), with a minimum overlap length of 30 bp, as seen in Table 1. All PCRs were carried out on chromosomal DNA of C. difficile 630Δerm (76, 77) using Q5 polymerase (New England Biolabs). The region upstream (~950 bp) and the coding region for the first 3 amino acids of hpdB were amplified using primers oWKS-1545 and oWKS-1546. The coding region for the last 3 amino acids of hpdA and the downstream region (~950 bp) were amplified using oWKS-1547 and oWKS-1548. The vector was amplified from pMTL-SC7215 using primers oWKS-1537 and oWKS-1538. One hundred nanograms of vector DNA was assembled with a threefold excess of the two other PCR fragments using Gibson Assembly Master Mix (New England Biolabs) for 30 min at 50°C and transformed into Escherichia coli DH5α. Transformants were screened by colony PCR using primers oWKS-1539 and oWKS-1540. Plasmids with the correct insert size were verified by Sanger sequencing, yielding pWKS1811. Purified pWKS1811 was transformed into E. coli CA434 (81), which was subsequently used as a donor to introduce the plasmid into C. difficile 630Δerm by conjugation. Transconjugants were selected on BHI agar supplemented with yeast extract (5 g/liter; Sigma), 15 µg/ml thiamphenicol, and C. difficile-selective supplement (CDSS; Oxoid) (BYTC plates) for 6 days. Several colonies were patched to fresh plates and checked for single-crossover integration of the pWKS1811 plasmid using PCR. Such a clone was subsequently plated onto BHI agar with CDSS but without thiamphenicol and incubated for 96 h to allow the second crossover event to occur. Colonies from this plate were harvested into 500 µl PBS, serially diluted, and plated onto minimal agar containing 50 µg/ml of 5-fluorocytosine (Sigma) (CDMM-5FC plates) (51). Colonies were screened for loss of the plasmid by patching on fresh BYTC and CDMM-5FC plates. Colonies that had lost the plasmid, as evidenced by thiamphenicol sensitivity, were grown in BHI broth supplemented with 5 g/liter yeast extract, and DNA was isolated using the DNeasy blood and tissue kit (Qiagen). The presence of the chromosomal deletion was verified by PCR using primers oWKS-1549 and oWKS-1550 and Sanger sequencing of the PCR product using primers oWKS-1545 and oWKS-1548. This yielded an unmarked C. difficile Δhpd strain (AP58) with the entire up- and downstream region of the operon intact but with the hpdBCA coding regions effectively removed.
TABLE 1
TABLE 1 Oligonucleotides used in this study
NameSequence (5′→3′)Descriptiona
oWKS-1537TAGGGTAACAAAAAACACCGRF311; reverse primer for amplification of vector (85)
oWKS-1538CCTTTTTGATAATCTCATGACCRF312; forward primer for amplification of vector (85)
oWKS-1539GGATTTCACATTTGCCGTTTTGTAAACRF21; forward primer for screening inserts in vector (85)
oWKS-1540GATCTTTTCTACGGGGTCTGACRF22; for screening inserts in vector (85)
oWKS-1545CGTAGAAATACGGTGTTTTTTGTTACCCTAATCTGGAGGTCATACTCACForward primer for upstream region of hpd operon
oWKS-1546TTAATTTTAGAAAGCTTGACTCATTTCTTCCCCReverse primer for upstream region of hpd operon
oWKS-1547GAAGAAATGAGTCAAGCTTTCTAAAATTAAATACAAGTTTTAATTAAAAAAGForward primer for downstream region of hpd operon
oWKS-1548GGGATTTTGGTCATGAGATTATCAAAAAGGTAACAGATGGAACAATCATTATAAAATAAATATTTTTACReverse primer for downstream region of hpd operon
oWKS-1549TGGTGGTGTAGTTCCAGAAGForward primer in the gcp gene, upstream from the hpd operon
oWKS-1550GAAGTCCACTTACAGGCATACCReverse primer in cd0156, downstream from the hpd operon
a
RF311, RF312, RF21, and RF22 are the primer designations used in reference 85.

Coculturing experiments.

The effect of C. albicans on C. difficile growth was determined by diluting fresh cultures of both strains to an optical density at 600 nm (OD600) of 0.01 in a total volume of 10 ml and incubating for 30 h under anaerobic conditions at 37°C in test tubes. Growth was assessed by determining the OD600 at 0, 2, 4, 6, 8, and 30 h after inoculation.
The growth of the individual species in both monoculture and coculture was assessed at all time points by performing serial dilution and spiral plating the samples on either YPD agar or BHI agar supplemented with 5% (vol/vol) defibrinated sheep blood (Biotrading Benelux, Mijdrecht, the Netherlands). Both types of plates were incubated under both aerobic and anaerobic conditions for 24 h, as aerobic conditions do not support the growth on plates of C. difficile and anaerobic conditions do not support the growth of C. albicans on BHI agar within 24 h.

Adhesion assay.

Adhesion of bacteria was analyzed using the Bioflux Z1000 platform (Fluxion Biosciences, Inc., South San Francisco, CA, USA) as described previously (82). The Bioflux was operated using the anaerobic air mixture, which resulted in (near) anaerobiosis of the channel within 15 min (unpublished observations). Briefly, the microscope stage was heated to 37°C and all solutions used were warmed to 37°C prior to use. PBS was flowed through the channels at 1 dyn/cm2 until the channels were free of air. Subsequently, 10% fetal bovine serum (product number F7524; Sigma) in PBS was flowed through the channels of a Fluxion 48-well plate for 30 min to coat the channels. C. albicans in yeast nitrogen base containing 0.5% glucose (YNB) at an OD600 of 0.1 was introduced into the channels from the output well. Subsequently, the flow was stopped and C. albicans was allowed to adhere for 15 to 30 min. Then, YNB was flowed through the channels at 0.5 dyn/cm2 to allow for hypha formation for 2.5 h. C. difficile from a liquid preculture was harvested by centrifugation at 10,000 × g for 1 min and resuspended in BHI to an OD600 of 0.2. These cells were then stained with LIVE/DEAD BacLight bacterial viability stain (Invitrogen) and passed over the hyphae at 0.5 dyn/cm2. Adhesion was visualized every minute for a total of 25 min using bright-field and fluorescent filter sets (60× objective; for fluorescein isothiocyanate [FITC], excitation wavelengths were 475/40 nm and band-pass [BP] wavelengths were 530/50 nm, and for red fluorescent dye, excitation wavelengths were 545/25 nm and BP wavelengths were 605/70 nm). Images were analyzed using ImageJ version 1.49 (83).

Preparation of conditioned medium.

To prepare conditioned medium, fresh cultures of each strain were grown as described above. Bacteria were removed by centrifugation (5,000 × g for 10 min), and the supernatant was subsequently filter sterilized (0.2 µm) and stored at −20°C until further use.

Hypha formation assay.

To assess the influence of the conditioned medium on hypha formation, the BioFlux microfluidics platform (Fluxion) was used. Briefly, C. albicans yeast cells (OD600 of 0.1) were allowed to adhere to the surface as described above for the adhesion assay. After 30 min, conditioned medium was continuously introduced into the channel at 0.5 dyn/cm2. Hypha formation was visualized using automated bright-field microscopy (Carl Zeiss Observer Z1) at 3 different locations per channel every 5 min for 3 h. The images were analyzed using ImageJ version 1.49 (83).

Fractionation of conditioned medium.

To investigate which secreted component was responsible for the effect on hypha formation and adherence, conditioned medium was fractionated. Fresh BHI spiked with 5% p-cresol and C. difficile-conditioned BHI were run on a C4 column (Vydac 214TP C4; Grace Davison Discovery Sciences) using a reverse-phase HPLC system (AS-1555, PU-980, LG-980-02, and DG-980-50; Jasco) equilibrated in 0.1% trifluoroacetic acid. Elution was performed with a linear gradient of 30 to 45% acetonitrile containing 0.1% trifluoroacetic acid in 30.5 min at a flow rate of 4 ml/min. The absorbance of the effluent was monitored at 214 nm, and fractions were collected separately using a fraction collector. The fractions were lyophilized in a rotational vacuum concentrator (RVC 2-25 plus; Martin Christ) and stored at −20°C until further use.

p-Cresol MIC assay.

To assess the MIC of p-cresol toward C. albicans, a planktonic culture was prepared as described above. The range of concentrations of p-cresol (0.1% to 0% with 0.01% [wt/vol] increments in BHI) were prepared in final volumes of 990 µl. Subsequently, 10 µl C. albicans culture was added to each p-cresol dilution to a final OD600 of ≈0.05. A 200-µl amount of each dilution was added in triplicate to the wells of a microtiter plate (Greiner), and the plates incubated for 16 h at 30°C under aerobic conditions. Prior to determining the final OD600 and the MIC, all suspensions were resuspended by pipetting to homogenize the well contents.

NMR validation of the C. difficile Δhpd strain.

All chemicals used for sample preparation were purchased from Sigma-Aldrich (Germany), except for sodium trimethylsilylpropionate-d4 (TMSP-2,2,3,3-D4 [TMSP]), which was purchased from Cambridge Isotope Laboratories, Inc. (United Kingdom). Frozen conditioned medium samples were allowed to thaw at 4°C. A 400-µl amount of each sample was mixed with 800 µl of ice-cold methanol in an Eppendorf tube and immediately placed at −30°C for 10 min to initiate protein precipitation. Subsequently, the mixtures were centrifuged at 16,000 × g at 4°C for 20 min, and the supernatants were collected and dried under a nitrogen gas stream. The dried material was reconstituted with 0.25 ml of phosphate buffer solution in D2O (150 mM K2HPO4, pH 7.4), including 0.4 mM of TMSP as the chemical shift reference standard for proton NMR, and transferred to 3-mm NMR tubes. All NMR data were recorded on a 14.1 T (600 MHz, 1 H) Bruker Avance II NMR spectrometer (Bruker Biospin, GmbH, Germany) equipped with a 5-mm TCI cryoprobe. One dimensional (1-D) proton NMR experiments were measured at 27°C, using the 1-D nuclear Overhauser effect spectroscopy (NOESY) with presaturation and spoil gradients (noesygppr1d) pulse sequence as implemented in the Topspin 3.0 library (Bruker Biospin GmbH, Germany), with presaturation for water signal suppression. Per sample, 65,536 data points were collected with 512 scans for a total of 59 min of acquisition time. Spectral data were Fourier transformed, phased, baseline corrected, and referenced to the TMSP peak at 0.00 ppm. The peaks of p-cresol, p-hydroxyphenylacetate (p-HPA), and l-tyrosine were annotated using the reference spectra of the Bruker Biorefcode database and by 2-dimensional (2-D) NMR spectroscopy (data not shown).

Crystal violet assay.

Biofilms were allowed to form in a microtiter plate as previously described (84). Four different media were introduced to the wells before incubation: BHI, C. difficile Δhpd-conditioned medium (Δhpd CM), C. difficile 630Δerm-conditioned medium (630Δerm CM), and BHI spiked with 0.1% p-cresol. After incubation, wells were thoroughly washed with PBS, followed by the addition of 0.2% (wt/vol) crystal violet in demineralized water. After 10 min of incubation, wells were washed with PBS to remove excess crystal violet. To quantify biofilm formation, crystal violet was extracted from the cells using isopropanol with 1 N HCl, and the absorption was determined at 590 nm.

Statistical analyses.

The significance of the data was analyzed using Student’s t test. Differences were deemed significant if the P value was <0.05.

ACKNOWLEDGMENTS

We thank Kamran Nazmi for his technical assistance and Andrea C. Hoogenkamp O'Brien for language editing and proofreading. We acknowledge the Minton laboratory for their kind gift of the allelic-exchange plasmids and the Fagan laboratory for their helpful discussions.
Work in the group of W.K.S. is supported in part by a Gisela Their Fellowship (LUMC) and a Vidi Fellowship of the Netherlands Organization for Scientific Research (NWO). The Bioflux Z1000 system was funded by a grant to B.P.K. from the Division for Earth and Life Sciences (ALW) with financial aid from the Netherlands Organization for Scientific Research (NWO). B.P.K. is supported by a grant from the University of Amsterdam for research into the focal point Oral Infections and Inflammation.

Supplemental Material

File (sph005162174sf1.tif)
ASM does not own the copyrights to Supplemental Material that may be linked to, or accessed through, an article. The authors have granted ASM a non-exclusive, world-wide license to publish the Supplemental Material files. Please contact the corresponding author directly for reuse.

REFERENCES

1.
Smits WK, Lyras D, Lacy BD, Wilcox MH, and Kuijper EJ. 2016. Clostridium difficile infection. Nat Rev Dis Primers2:16020.
2.
Abt MC, McKenney PT, and Pamer EG. 2016. Clostridium difficile colitis: pathogenesis and host defence. Nat Rev Microbiol14:609–620.
3.
Shen A. 2012. Clostridium difficile toxins: mediators of inflammation. J Innate Immun4:149–158.
4.
Seekatz AM, Rao K, Santhosh K, and Young VB. 2016. Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent Clostridium difficile infection. Genome Med8:1.
5.
Pépin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, Pépin K, and Chouinard D. 2004. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ171:466–472.
6.
Labbé AC, Poirier L, Maccannell D, Louie T, Savoie M, Béliveau C, Laverdière M, and Pépin J. 2008. Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob Agents Chemother52:3180–3187.
7.
Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, and Simmons RL. 2002. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg235:363–372.
8.
Kuijper EJ, Barbut F, Brazier JS, Kleinkauf N, Eckmanns T, Lambert ML, Drudy D, Fitzpatrick F, Wiuff C, Brown DJ, Coia JE, Pituch H, Reichert P, Even J, Mossong J, Widmer AF, Olsen KE, Allerberger F, Notermans DW, Delmee M, Coignard B, Wilcox M, Patel B, Frei R, Nagy E, Bouza E, Marin M, Akerlund T, Virolainen-Julkunen A, Lyytikainen O, Kotila S, Ingebretsen A, Smyth B, Rooney P, Poxton IR, and Monnet DL. 2008. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill13:pii=18942. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18942 .
9.
Kuijper EJ Coignard B Tüll P ESCMID Study Group for Clostridium difficile, EU Member States, European Centre for Disease Prevention and Control. 2006. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect12(Suppl 6):2–18.
10.
Rupnik M, Wilcox MH, and Gerding DN. 2009. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol7:526–536.
11.
McGlone SM, Bailey RR, Zimmer SM, Popovich MJ, Tian Y, Ufberg P, Muder RR, and Lee BY. 2012. The economic burden of Clostridium difficile. Clin Microbiol Infect18:282–289.
12.
O’Brien JA, Lahue BJ, Caro JJ, and Davidson DM. 2007. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol28:1219–1227.
13.
Carroll KC and Bartlett JG. 2011. Biology of Clostridium difficile: implications for epidemiology and diagnosis. Annu Rev Microbiol65:501–521.
14.
Johanesen PA, Mackin KE, Hutton ML, Awad MM, Larcombe S, Amy JM, and Lyras D. 2015. Disruption of the gut microbiome: Clostridium difficile infection and the threat of antibiotic resistance. Genes6:1347–1360.
15.
Gerding DN and Johnson S. 2010. Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis51:1306–1313.
16.
Spigaglia P, Barbanti F, Mastrantonio P, European Study Group on Clostridium, and difficile (ESGCD). 2011. Multidrug resistance in European Clostridium difficile clinical isolates. J Antimicrob Chemother66:2227–2234.
17.
Kennedy MJ, Volz PA, Edwards CA, and Yancey RJ. 1987. Mechanisms of association of Candida albicans with intestinal mucosa. J Med Microbiol24:333–341.
18.
Ruiz-Sánchez D, Calderón-Romero L, Sánchez-Vega JT, and Tay J. 2002. Intestinal candidiasis. A clinical report and comments about this opportunistic pathology. Mycopathologia156:9–11.
19.
Metwalli KH, Khan SA, Krom BP, and Jabra-Rizk MA. 2013. Streptococcus mutans, Candida albicans, and the human mouth: a sticky situation. PLoS Pathog9:e1003616.
20.
Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, and White TC. 2012. Hidden killers: human fungal infections. Sci Transl Med4:165rv113.
21.
Lo HJ, Köhler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, and Fink GR. 1997. Nonfilamentous C. albicans mutants are avirulent. Cell90:939–949.
22.
Murad AM, Leng P, Straffon M, Wishart J, Macaskill S, MacCallum D, Schnell N, Talibi D, Marechal D, Tekaia F, d’Enfert C, Gaillardin C, Odds FC, and Brown AJ. 2001. NRG1 represses yeast-hypha morphogenesis and hypha-specific gene expression in Candida albicans. EMBO J20:4742–4752.
23.
Mayer FL, Wilson D, and Hube B. 2013. Candida albicans pathogenicity mechanisms. Virulence4:119–128.
24.
Schlecht LM, Peters BM, Krom BP, Freiberg JA, Hänsch GM, Filler SG, Jabra-Rizk MA, and Shirtliff ME. 2015. Systemic Staphylococcus aureus infection mediated by Candida albicans hyphal invasion of mucosal tissue. Microbiology161:168–181.
25.
El-Azizi MA, Starks SE, and Khardori N. 2004. Interactions of Candida albicans with other Candida spp. and bacteria in the biofilms. J Appl Microbiol96:1067–1073.
26.
Fox EP, Cowley ES, Nobile CJ, Hartooni N, Newman DK, and Johnson AD. 2014. Anaerobic bacteria grow within Candida albicans biofilms and induce biofilm formation in suspension cultures. Curr Biol24:2411–2416.
27.
Harriott MM and Noverr MC. 2010. Ability of Candida albicans mutants to induce Staphylococcus aureus vancomycin resistance during polymicrobial biofilm formation. Antimicrob Agents Chemother54:3746–3755.
28.
Mukherjee PK, Sendid B, Hoarau G, Colombel J-F, Poulain D, and Ghannoum MA. 2015. Mycobiota in gastrointestinal diseases. Nat Rev Gastroenterol Hepatol12:77–87.
29.
Mason KL, Erb Downward JR, Mason KD, Falkowski NR, Eaton KA, Kao JY, Young VB, and Huffnagle GB. 2012. Candida albicans and bacterial microbiota interactions in the cecum during recolonization following broad-spectrum antibiotic therapy. Infect Immun80:3371–3380.
30.
Raponi G, Visconti V, Brunetti G, and Ghezzi MC. 2014. Clostridium difficile infection and Candida colonization of the gut: is there a correlation?Clin Infect Dis59:1648–1649.
31.
Guastalegname M, Russo A, Falcone M, Giuliano S, and Venditti M. 2013. Candidemia subsequent to severe infection due to Clostridium difficile: is there a link?Clin Infect Dis57:772–774.
32.
Russo A, Falcone M, Fantoni M, Murri R, Masucci L, Carfagna P, Ghezzi MC, Posteraro B, Sanguinetti M, and Venditti M. 2015. Risk factors and clinical outcomes of candidaemia in patients treated for Clostridium difficile infection. Clin Microbiol Infect21:493.e1–493.e4.
33.
Manian FA and Bryant A. 2013. Does Candida species overgrowth protect against Clostridium difficile infection?Clin Infect Dis56:464–465.
34.
Nerandzic MM, Mullane K, Miller MA, Babakhani F, and Donskey CJ. 2012. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis55(Suppl 2):S121–S126.
35.
Dumitru R, Hornby JM, and Nickerson KW. 2004. Defined anaerobic growth medium for studying Candida albicans basic biology and resistance to eight antifungal drugs. Antimicrob Agents Chemother48:2350–2354.
36.
Webster CE and Odds FC. 1987. Growth of pathogenic Candida isolates anaerobically and under elevated concentrations of CO2 in air. J Med Vet Mycol25:47–53.
37.
Hall IC and O’Toole E. 1935. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child49:390–402.
38.
He G, Shankar RA, Chzhan M, Samouilov A, Kuppusamy P, and Zweier JL. 1999. Noninvasive measurement of anatomic structure and intraluminal oxygenation in the gastrointestinal tract of living mice with spatial and spectral EPR imaging. Proc Natl Acad Sci U S A96:4586–4591.
39.
Wang LH, He Y, Gao Y, Wu JE, Dong YH, He C, Wang SX, Weng LX, Xu JL, Tay L, Fang RX, and Zhang LH. 2004. A bacterial cell-cell communication signal with cross-kingdom structural analogues. Mol Microbiol51:903–912.
40.
Boon C, Deng Y, Wang L-H, He Y, Xu J-L, Fan Y, Pan SQ, and Zhang L-H. 2008. A novel DSF-like signal from Burkholderia cenocepacia interferes with Candida albicans morphological transition. ISME J2:27–36.
41.
McLean RJC. 2014. Normal bacterial flora may inhibit Candida albicans biofilm formation by autoinducer-2. Front Cell Infect Microbiol4:117.
42.
Shareck J and Belhumeur P. 2011. Modulation of morphogenesis in Candida albicans by various small molecules. Eukaryot Cell10:1004–1012.
43.
Levett PN. 1987. Production of p-cresol by Clostridium difficile on different basal media. Lett Appl Microbiol5:71–73.
44.
Sivsammye G and Sims HV. 1990. Presumptive identification of Clostridium difficile by detection of p-cresol in prepared peptone yeast glucose broth supplemented with p-hydroxyphenylacetic acid. J Clin Microbiol28:1851–1853.
45.
Hafiz S and Oakley CL. 1976. Clostridium difficile: isolation and characteristics. J Med Microbiol9:129–136.
46.
Nowak A and Libudzisz Z. 2006. Influence of phenol, p-cresol and indole on growth and survival of intestinal lactic acid bacteria. Anaerobe12:80–84.
47.
Heipieper HJ, Keweloh H, and Rehm HJ. 1991. Influence of phenols on growth and membrane permeability of free and immobilized Escherichia coli. Appl Environ Microbiol57:1213–1217.
48.
Selmer T and Andrei PI. 2001. p-Hydroxyphenylacetate decarboxylase from Clostridium difficile. Eur J Biochem268:1363–1372.
49.
Andrei PI, Pierik AJ, Zauner S, Andrei-Selmer LC, and Selmer T. 2004. Subunit composition of the glycyl radical enzyme p-hydroxyphenylacetate decarboxylase. A small subunit, HpdC, is essential for catalytic activity. Eur J Biochem271:2225–2230.
50.
Dawson LF, Donahue EH, Cartman ST, Barton RH, Bundy J, McNerney R, Minton NP, and Wren BW. 2011. The analysis of para-cresol production and tolerance in Clostridium difficile 027 and 012 strains. BMC Microbiol11:86.
51.
Cartman ST, Kelly ML, Heeg D, Heap JT, and Minton NP. 2012. Precise manipulation of the Clostridium difficile chromosome reveals a lack of association between the tcdC genotype and toxin production. Appl Environ Microbiol78:4683–4690.
52.
Bachtiar EW, Bachtiar BM, Jarosz LM, Amir LR, Sunarto H, Ganin H, Meijler MM, and Krom BP. 2014. AI-2 of Aggregatibacter actinomycetemcomitans inhibits Candida albicans biofilm formation. Front Cell Infect Microbiol4:94.
53.
Sproule-Willoughby KM, Stanton MM, Rioux KP, McKay DM, Buret AG, and Ceri H. 2010. In vitro anaerobic biofilms of human colonic microbiota. J Microbiol Methods83:296–301.
54.
Wezensky SJ and Cramer RA. 2011. Implications of hypoxic microenvironments during invasive aspergillosis. Med Mycol49(Suppl 1):S120–S124.
55.
Land GA, McDonald WC, Stjernholm RL, and Friedman L. 1975. Factors affecting filamentation in Candida albicans: changes in respiratory activity of Candida albicans during filamentation. Infect Immun12:119–127.
56.
Somerville GA and Proctor RA. 2013. Cultivation conditions and the diffusion of oxygen into culture media: the rationale for the flask-to-medium ratio in microbiology. BMC Microbiol13:9.
57.
Dione N, Khelaifia S, Lagier J-C, and Raoult D. 2015. The aerobic activity of metronidazole against anaerobic bacteria. Int J Antimicrob Agents45:537–540.
58.
Marteyn B, Scorza FB, Sansonetti PJ, and Tang C. 2011. Breathing life into pathogens: the influence of oxygen on bacterial virulence and host responses in the gastrointestinal tract. Cell Microbiol13:171–176.
59.
Rigottier-Gois L. 2013. Dysbiosis in inflammatory bowel diseases: the oxygen hypothesis. ISME J7:1256–1261.
60.
Theriot CM, Koenigsknecht MJ, Carlson PE, Hatton GE, Nelson AM, Li B, Huffnagle GB, Li J, and Young VB. 2014. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun5:3114.
61.
Hansen AK and Nielsen DS. 2014. Handbook of laboratory animal bacteriology, 2nd ed, p 133–166. CRC Press, Boca Raton, FL.
62.
Krom BP, Levy N, Meijler MM, and Jabra-Rizk MA. 2016. Farnesol and Candida albicans: quorum sensing or not quorum sensing?Isr J Chem56:295–301.
63.
Ha KC and White TC. 1999. Effects of azole antifungal drugs on the transition from yeast cells to hyphae in susceptible and resistant isolates of the pathogenic yeast Candida albicans. Antimicrob Agents Chemother43:763–768.
64.
Brand A. 2012. Hyphal growth in human fungal pathogens and its role in virulence. Int J Microbiol2012:517529.
65.
Low CF, Chong PP, Yong PV, Lim CS, Ahmad Z, and Othman F. 2008. Inhibition of hyphae formation and SIR2 expression in Candida albicans treated with fresh Allium sativum (garlic) extract. J Appl Microbiol105:2169–2177.
66.
Khan A, Ahmad A, Ahmad Khan L, Padoa CJ, van Vuuren S, and Manzoor N. 2015. Effect of two monoterpene phenols on antioxidant defense system in Candida albicans. Microb Pathog80:50–56.
67.
Cordeiro RDA, Teixeira CE, Brilhante RS, Castelo-Branco DS, Alencar LP, de Oliveira JS, Monteiro AJ, Bandeira TJ, Sidrim JJ, Moreira JL, and Rocha MF. 2015. Exogenous tyrosol inhibits planktonic cells and biofilms of Candida species and enhances their susceptibility to antifungals. FEMS Yeast Res15:fov012.
68.
Monteiro DR, Feresin LP, Arias LS, Barão VA, Barbosa DB, and Delbem AC. 2015. Effect of tyrosol on adhesion of Candida albicans and Candida glabrata to acrylic surfaces. Med Mycol53:656–665.
69.
Freires IA, Queiroz VC, Furletti VF, Ikegaki M, de Alencar SM, Duarte MC, and Rosalen PL. 2016. Chemical composition and antifungal potential of Brazilian propolis against Candida spp. J Mycol Med26:122–132.
70.
Panwar R, Pemmaraju SC, Sharma AK, and Pruthi V. 2016. Efficacy of ferulic acid encapsulated chitosan nanoparticles against Candida albicans biofilm. Microb Pathog95:21–31.
71.
De Vita D, Friggeri L, D’Auria FD, Pandolfi F, Piccoli F, Panella S, Palamara AT, Simonetti G, Scipione L, Di Santo R, Costi R, and Tortorella S. 2014. Activity of caffeic acid derivatives against Candida albicans biofilm. Bioorg Med Chem Lett24:1502–1505.
72.
Pointer BR, Boyer MP, and Schmidt M. 2015. Boric acid destabilizes the hyphal cytoskeleton and inhibits invasive growth of Candida albicans. Yeast32:389–398.
73.
Doke SK, Raut JS, Dhawale S, and Karuppayil SM. 2014. Sensitization of Candida albicans biofilms to fluconazole by terpenoids of plant origin. J Gen Appl Microbiol60:163–168.
74.
Fazly A, Jain C, Dehner AC, Issi L, Lilly EA, Ali A, Cao H, Fidel PL, Rao RP, and Kaufman PD. 2013. Chemical screening identifies filastatin, a small molecule inhibitor of Candida albicans adhesion, morphogenesis, and pathogenesis. Proc Natl Acad Sci U S A110:13594–13599.
75.
Pierce CG, Chaturvedi AK, Lazzell AL, Powell AT, Saville SP, McHardy SF, and Lopez-Ribot JL. 2015. A novel small molecule inhibitor of Candida albicans biofilm formation, filamentation and virulence with low potential for the development of resistance. NPJ Biofilms Microbiomes1:15012.
76.
Van Eijk E, Anvar SY, Browne HP, Leung WY, Frank J, Schmitz AM, Roberts AP, and Smits WK. 2015. Complete genome sequence of the Clostridium difficile laboratory strain 630Δerm reveals differences from strain 630, including translocation of the mobile element CTn5. BMC Genomics16:31.
77.
Hussain HA, Roberts AP, and Mullany P. 2005. Generation of an erythromycin-sensitive derivative of Clostridium difficile strain 630 (630Deltaerm) and demonstration that the conjugative transposon Tn916DeltaE enters the genome of this strain at multiple sites. J Med Microbiol54:137–141.
78.
Myers GS, Rasko DA, Cheung JK, Ravel J, Seshadri R, DeBoy RT, Ren Q, Varga J, Awad MM, Brinkac LM, Daugherty SC, Haft DH, Dodson RJ, Madupu R, Nelson WC, Rosovitz MJ, Sullivan SA, Khouri H, Dimitrov GI, Watkins KL, Mulligan S, Benton J, Radune D, Fisher DJ, Atkins HS, Hiscox T, Jost BH, Billington SJ, Songer JG, McClane BA, Titball RW, Rood JI, Melville SB, and Paulsen IT. 2006. Skewed genomic variability in strains of the toxigenic bacterial pathogen, Clostridium perfringens. Genome Res16:1031–1040.
79.
Fonzi WA and Irwin MY. 1993. Isogenic strain construction and gene mapping in Candida albicans. Genetics134:717–728.
80.
Gibson DG, Young L, Chuang R-Y, Venter JC, Hutchison CA, and Smith HO. 2009. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods6:343–345.
81.
Purdy D, O’Keeffe TA, Elmore M, Herbert M, McLeod A, Bokori-Brown M, Ostrowski A, and Minton NP. 2002. Conjugative transfer of clostridial shuttle vectors from Escherichia coli to Clostridium difficile through circumvention of the restriction barrier. Mol Microbiol46:439–452.
82.
Benoit MR, Conant CG, Ionescu-Zanetti C, Schwartz M, and Matin A. 2010. New device for high-throughput viability screening of flow biofilms. Appl Environ Microbiol76:4136–4142.
83.
Schneider CA, Rasband WS, and Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image analysis. Nat Methods9:671–675.
84.
Krom BP, Cohen JB, McElhaney Feser GE, and Cihlar RL. 2007. Optimized candidal biofilm microtiter assay. J Microbiol Methods68:421–423.
85.
Kirk JA and Fagan RP. 2016. Heat shock increases conjugation efficiency in Clostridium difficile. Anaerobe42:1–5.

Information & Contributors

Information

Published In

cover image mSphere
mSphere
Volume 1Number 628 December 2016
eLocator: 10.1128/msphere.00187-16
Editor: Michael J. Imperiale, University of Michigan

History

Received: 5 July 2016
Accepted: 30 September 2016
Published online: 9 November 2016

Keywords:

  1. Candida albicans
  2. Clostridium difficile
  3. interspecies interactions

Contributors

Authors

Pim T. van Leeuwen
Department of Preventive Dentistry, Academic Centre for Dentistry Amsterdam (ACTA), Free University of Amsterdam and the University of Amsterdam, Amsterdam, The Netherlands
Department of Medical Microbiology, Leiden University Medical Center (LUMC), Leiden, The Netherlands
Jasper M. van der Peet
Department of Preventive Dentistry, Academic Centre for Dentistry Amsterdam (ACTA), Free University of Amsterdam and the University of Amsterdam, Amsterdam, The Netherlands
Floris J. Bikker
Department of Oral Biochemistry, Academic Centre for Dentistry Amsterdam (ACTA), Free University of Amsterdam and the University of Amsterdam, Amsterdam, The Netherlands
Michel A. Hoogenkamp
Department of Preventive Dentistry, Academic Centre for Dentistry Amsterdam (ACTA), Free University of Amsterdam and the University of Amsterdam, Amsterdam, The Netherlands
Ana M. Oliveira Paiva
Department of Medical Microbiology, Leiden University Medical Center (LUMC), Leiden, The Netherlands
Sarantos Kostidis
Center for Proteomics and Metabolomics, Leiden University Medical Center (LUMC), Leiden, The Netherlands
Oleg A. Mayboroda
Center for Proteomics and Metabolomics, Leiden University Medical Center (LUMC), Leiden, The Netherlands
Wiep Klaas Smits
Department of Medical Microbiology, Leiden University Medical Center (LUMC), Leiden, The Netherlands
Bastiaan P. Krom
Department of Preventive Dentistry, Academic Centre for Dentistry Amsterdam (ACTA), Free University of Amsterdam and the University of Amsterdam, Amsterdam, The Netherlands

Editor

Michael J. Imperiale
Editor
University of Michigan

Notes

Address correspondence to Wiep Klaas Smits, [email protected], or Bastiaan P. Krom, [email protected].

Metrics & Citations

Metrics

Note: There is a 3- to 4-day delay in article usage, so article usage will not appear immediately after publication.

Citation counts come from the Crossref Cited by service.

Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.

View Options

Figures and Media

Figures

Media

Tables

Share

Share

Share the article link

Share with email

Email a colleague

Share on social media

American Society for Microbiology ("ASM") is committed to maintaining your confidence and trust with respect to the information we collect from you on websites owned and operated by ASM ("ASM Web Sites") and other sources. This Privacy Policy sets forth the information we collect about you, how we use this information and the choices you have about how we use such information.
FIND OUT MORE about the privacy policy